Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medplus Health ServicesNSE:MEDPLUS -0.97%78 Return-on-Tangible-Equity is 13.29% as of Mar. 2026, which is 88% above its 10-year median of 7.06. GuruFocus rates NSE:MEDPLUS with a GF Score™ of 78/100 and a GF Value™ of ₹961.24 (Modestly Undervalued). Among 577 Healthcare Providers & Services companies, Medplus Health Services ranks better than 53.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medplus Health Services's annualized net income for the quarter that ended in Mar. 2026 was ₹2,559 Mil. Medplus Health Services's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹19,260 Mil. Therefore, Medplus Health Services's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 13.29%.
The historical rank and industry rank for Medplus Health Services's Return-on-Tangible-Equity or its related term are showing as below:
NSE:MEDPLUS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.6 Med: 7.06 Max: 12.18
Current: 12.18
During the past 8 years, Medplus Health Services's highest Return-on-Tangible-Equity was 12.18%. The lowest was 0.60%. And the median was 7.06%.
NSE:MEDPLUS's Return-on-Tangible-Equity is ranked better than 53.73% of 577
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs NSE:MEDPLUS: 12.18
Medplus Health Services (NSE:MEDPLUS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medplus Health Services Return-on-Tangible-Equity Related Terms
Medplus Health Services Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medplus Health Services's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medplus Health Services Return-on-Tangible-Equity Chart
Medplus Health Services Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Medplus Health Services's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medplus Health Services Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medplus Health Services's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medplus Health Services's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.29% mean?
Medplus Health Services (NSE:MEDPLUS) has a Return-on-Tangible-Equity of 13.29% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medplus Health Services and its competitors. This is 88% above median its historical median of 7.06. Over the past decade, Medplus Health Services' Return-on-Tangible-Equity has ranged from 0.60 to 12.18. According to the industry distribution chart, Medplus Health Services ranks #267 out of 577 companies in the Healthcare Providers & Services industry, placing it in the top 46.3%.
Is Medplus Health Services' Return-on-Tangible-Equity too high?
Medplus Health Services' current Return-on-Tangible-Equity of 13.29% is 88% above median its 10-year median of 7.06. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 12.18. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.13. Medplus Health Services' value of 13.29% is 31.2% above this industry median. Based on the distribution chart, Medplus Health Services ranks #267 out of 577 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medplus Health Services has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medplus Health Services' Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Medplus Health Services ranks #267 out of 577 companies for Return-on-Tangible-Equity. This puts Medplus Health Services in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.13. Medplus Health Services' value of 13.29% is 31.2% above this benchmark. Historically, Medplus Health Services' own Return-on-Tangible-Equity has ranged from 0.60 to 12.18 over the past decade. While the company's 10-year median is 7.06 vs. the industry median of 10.13, Medplus Health Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 577 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medplus Health Services's current Return-on-Tangible-Equity of 13.29% is 31.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medplus Health Services and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medplus Health Services's current Return-on-Tangible-Equity is 13.29%, which is 88% above median its own 10-year median of 7.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medplus Health Services stock overvalued right now?
Based on GuruFocus' analysis, Medplus Health Services (NSE:MEDPLUS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹961.24, compared to a current price of ₹801.10 — trading 16.7% below its estimated fair value. The current Return-on-Tangible-Equity is 13.29%, which is 88% above median its 10-year median of 7.06 and 31.2% above the Healthcare Providers & Services industry median of 10.13. Medplus Health Services' overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medplus Health Services (NSE:MEDPLUS), the current Return-on-Tangible-Equity is 13.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medplus Health Services (NSE:MEDPLUS) Overvalued in 2026?
Based on GuruFocus' analysis, Medplus Health Services stock appears to be undervalued.
The current stock price of ₹801.10 is trading 16.7% below its estimated GF Value™ of ₹961.24.
GuruFocus considers Medplus Health Services to be Modestly Undervalued.
Key valuation signals for NSE:MEDPLUS:
Return-on-Tangible-Equity: 13.29% (88% above median its 10-year median of 7.06)
GF Value™: ₹961.24 vs. price of ₹801.10 (16.7% below fair value)
Industry Position: 31.2% above the Healthcare Providers & Services median (#267 of 577)
No single metric tells the full story. See the NSE:MEDPLUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medplus Health Services Ltd is a pharmacy retailer. It offers pharmaceutical and wellness products such as medicines, vitamins, medical devices, test kits, and others. The company also offers an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility. Its operating segments include Retail, Diagnostics, and Others.
78GF Score
Get the complete analysis for NSE:MEDPLUS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MEDPLUS has been successfully added to your 
